INSPRA

LOE Approaching

eplerenone

NDAORALTABLET
Approved
Sep 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Aldosterone Antagonists

Pharmacologic Class:

Aldosterone Antagonist

Clinical Trials (5)

NCT05198791Phase 2Recruiting

Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.

Started Feb 2022
400 enrolled
Myocardial Infarction, AcuteMyocardial Infarction With Nonobstructive Coronary ArteriesMyocardial Injury
NCT02629094Phase 2Terminated

Cardiometabolic Effects of Eplerenone in HIV Infection

Started Dec 2015
NCT01708798Phase 2/3Terminated

Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer

Started May 2014
44 enrolled
Breast Cancer
NCT01971593Phase 4Terminated

The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease

Started Aug 2013
26 enrolled
Tetralogy of FallotTransposition of the Great Vessels With an Arterial SwitchSingle Ventricle With a Fontan Palliation
NCT01586442Phase 3Completed

Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes

Started Mar 2012
62 enrolled
Heart FailureType 2 DiabetesGlucose Intolerance